The FLOW Kidney Trial Follow-Up: What Semaglutide Delivered for CKD Patients

FLOW established semaglutide as the first GLP-1 with a clear kidney-protection indication in adults with type 2 diabetes and chronic kidney disease. Follow-up data has extended the picture. Here's where FLOW stands as clinical evidence.

The FLOW Design and Primary Result

FLOW randomized adults with type 2 diabetes and chronic kidney disease to semaglutide or placebo, with the primary composite endpoint including major kidney disease events, kidney-cause death, and cardiovascular death. The trial was stopped early on efficacy grounds based on interim analysis showing clear benefit in the semaglutide arm.

The 24% reduction in the primary composite endpoint (compared to placebo) was clinically meaningful and reproducible across subgroups. Kidney function decline slowed measurably, and cardiovascular events tracked favorably alongside.

Follow-Up Extension

Extended follow-up beyond the primary readout has maintained the benefit signal. Patients continued on semaglutide showed preserved kidney function relative to placebo controls, and the CV benefit component remained meaningful. Discontinuation analyses suggest partial durability of benefit after stopping, though as with most chronic therapies, ongoing treatment appears required for sustained effect.

What FLOW Means for CKD Treatment

FLOW positions semaglutide as a fourth-pillar therapy for diabetic kidney disease alongside SGLT2 inhibitors, non-steroidal MRAs, and RAAS blockade. The four classes work through complementary mechanisms and, in patients who tolerate them, can be combined for additive effect. Nephrology guidelines have begun to incorporate GLP-1 therapy explicitly into CKD algorithms in patients with type 2 diabetes.

What FLOW Didn't Establish

FLOW was a diabetes-CKD trial. It didn't enroll non-diabetic CKD patients, so extrapolation to that population requires additional trials. It also didn't establish head-to-head superiority over SGLT2 inhibitors — the two classes appear complementary rather than substitutive based on mechanism.

Whether tirzepatide would produce similar or greater kidney benefits is an open question. No FLOW-equivalent trial has been completed for tirzepatide.

Practical Implications for Patients

For adults with type 2 diabetes and CKD, semaglutide is now a defensible addition to standard-of-care regimens on kidney-protection grounds beyond weight loss or glycemic control. Patients with these dual indications may find insurance coverage decisions favor semaglutide on renal protection when weight loss alone would have been denied.

Where to Start